At-Home Drug of Abuse Testing Industry Analysis, Share, Growth Drivers and Forecast by 2023

Global at-home DOA testing market is projected to attain a size of $831.9 million by 2023. The market is mainly driven by the increased production and trade of illicit drugs worldwide, growing use of illicit drugs amongst teenagers, and initiatives by government organizations to reduce the level of drug abuse.

Browse report sample at: https://www.psmarketresearch.com/market-analysis/at-home-doa-testing-market/report-sample

On the basis of various types of products, the at-home DOA testing market has been categorized into rapid DOA test kits and breath analyzers. The market for rapid DOA test kits is expected to witness faster growth during the forecast period, attributed to the increasing adoption of various types of rapid DOA test kits, including test cups and dip cards. Also, these test kits are much cheaper as compared to breath analyzers.

Further, the rapid DOA test kits are bifurcated into test cups, test strips, test dip cards, and other types of kits. Amongst all these, the DOA test cups dominated the global rapid DOA test kits market in 2017. Extensive use of test cups for at-home urine drug testing is a key factor driving the market for this product category.

Browse report at: https://www.psmarketresearch.com/market-analysis/at-home-doa-testing-market

The companies operating in the at-home DOA testing industry are acquiring other firms and establishing their presence in different economies to increase their market share. Abbott Laboratories (Abbott) being a major player in the production of at-home DOA testing products acquired Alere Inc. in 2017, to increase its share in the point-of-care testing diagnostics market. The addition of this business aligns with Abbott's strategy for the growth of company and complements the leadership positions across its other businesses, which include medical devices, nutritional supplements, and pharmaceuticals.

Some of the other key players in the at-home DOA testing industry are UCP Biosciences Inc., Orient New Life Medical Co. Ltd., Express Diagnostics Int’l Inc., Assure Tech (Hangzhou) Co. Ltd., Psychemedics Corporation, Confirm BioSciences, Phamatech Inc., Home Health (U.K.) Ltd., and Quest Products Inc.

Source: P&S Intelligence